Prevention and Treatment of Viral Infections

Core Concepts

Vaccines: prevention by training the immune system

A vaccine presents the immune system with a harmless version of a virus (or a piece of it), so memory lymphocytes form; if the real virus arrives later, the response is faster and stronger, often before symptoms develop. This is active immunity: the person's own body makes the antibodies and memory cells, and protection can last years. Vaccine types differ in what "harmless version" means. Live-attenuated vaccines use a weakened virus that replicates mildly, giving strong, long-lasting immunity, but they are generally avoided in people with severely weakened immune systems. Inactivated vaccines use killed virus; they are safer for immunocompromised people but often need boosters. Subunit vaccines use only a viral piece, such as a surface protein (hepatitis B, HPV), removing nearly all infection risk. mRNA vaccines deliver genetic instructions that make the host's own cells briefly produce a viral protein, which the immune system then learns to recognize (as in some COVID-19 vaccines).

When most of a population is immune, the virus struggles to find susceptible hosts — herd immunity. People who cannot be vaccinated are protected by the protection of those around them, which is why vaccination is a community act, not just a personal one.

Hygiene and public-health measures

Not every virus has a vaccine, so blocking transmission matters. Hand hygiene interrupts fecal–oral and contact spread; masks interrupt droplet and aerosol spread; condoms reduce sexual transmission; vector control (bed nets, mosquito control) breaks insect-borne links such as dengue. Quarantine separates people who may have been exposed but are not yet sick; isolation separates people who are actually infected. Contact tracing warns and tests everyone an infected person may have exposed. These measures work by assuming a transmission chain exists and breaking every possible link.

Antiviral drugs: attacking specific steps of the viral life cycle

Each antiviral jams one step of the replication cycle. Entry and uncoating inhibitors block attachment to the host cell or release of the genome. Nucleoside analogs masquerade as normal nucleotides; the viral polymerase incorporates the fake building block and the growing chain terminates (acyclovir for herpes, many HIV and hepatitis drugs). Reverse transcriptase inhibitors block HIV's enzyme that copies RNA into DNA — an enzyme human cells do not normally use, which is why the drug is selective. Protease inhibitors block the viral enzyme that chops polyproteins into functional pieces (HIV, hepatitis C). Neuraminidase inhibitors (oseltamivir) block the enzyme flu virus uses to detach from one cell and spread to the next; they work best started early.

Every antiviral targets a virus-specific or virus-enriched step, harming the virus more than the host. Because viruses mutate quickly, a single drug can be defeated; HIV is therefore treated with combinations of drug classes, so a virus resistant to one is still stopped by the others.

Treatment challenges: timing, resistance, and supportive care

Viral polymerases make copying errors, generating mutant viruses constantly; if a mutant survives a drug, it can become dominant under that drug's selective pressure — antiviral resistance, the same evolutionary logic as antibiotic resistance. Timing matters too: antivirals work best before the virus spreads widely, which is why flu antivirals are most effective when started within the first couple of days of symptoms. When no specific drug exists, care is supportive — fluids, fever control, rest, and treating complications — giving the immune system time to clear the infection.

Common Confusions